A simplified 6-Item clinician administered dissociative symptom scale (CADSS-6) for monitoring dissociative effects of sub-anesthetic ketamine infusions.

[1]  Nelson B Rodrigues,et al.  The effectiveness of repeated intravenous ketamine on depressive symptoms, suicidal ideation and functional disability in adults with major depressive disorder and bipolar disorder: Results from the Canadian Rapid Treatment Center of Excellence. , 2020, Journal of affective disorders.

[2]  Nelson B Rodrigues,et al.  Safety and tolerability of IV ketamine in adults with major depressive or bipolar disorder: results from the Canadian rapid treatment center of excellence , 2020, Expert opinion on drug safety.

[3]  C. Loo,et al.  Intravenous arketamine for treatment-resistant depression: open-label pilot study , 2020, European Archives of Psychiatry and Clinical Neuroscience.

[4]  R. Sutar,et al.  Pharmacotherapy for dissociative disorders: A systematic review , 2019, Psychiatry Research.

[5]  D. M. Lyons,et al.  Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism , 2019, Molecular Psychiatry.

[6]  R. Shelton,et al.  Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. , 2019, The American journal of psychiatry.

[7]  J. Talbot,et al.  Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A Randomized Controlled Trial. , 2019, The American journal of psychiatry.

[8]  M. Fava,et al.  Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD) , 2018, Molecular Psychiatry.

[9]  S. Wilkinson,et al.  Acute and Longer-Term Outcomes Using Ketamine as a Clinical Treatment at the Yale Psychiatric Hospital. , 2018, The Journal of clinical psychiatry.

[10]  E. Ballard,et al.  Features of dissociation differentially predict antidepressant response to ketamine in treatment-resistant depression. , 2018, Journal of affective disorders.

[11]  L. Davidson,et al.  Acute psychoactive effects of intravenous ketamine during treatment of mood disorders: Analysis of the Clinician Administered Dissociative State Scale. , 2018, Journal of affective disorders.

[12]  Kelly C. Lee,et al.  Low-dose ketamine for treatment resistant depression in an academic clinical practice setting. , 2017, Journal of affective disorders.

[13]  E. Ballard,et al.  The Effect of a Single Dose of Intravenous Ketamine on Suicidal Ideation: A Systematic Review and Individual Participant Data Meta-Analysis. , 2017, The American journal of psychiatry.

[14]  R. McIntyre,et al.  Strategies to mitigate dissociative and psychotomimetic effects of ketamine in the treatment of major depressive episodes: a narrative review , 2017, The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry.

[15]  M. Frye,et al.  A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders , 2017, JAMA psychiatry.

[16]  D. Luckenbaugh,et al.  Symptomatology and predictors of antidepressant efficacy in extended responders to a single ketamine infusion. , 2017, Journal of affective disorders.

[17]  Trina E. Chang,et al.  Ketamine augmentation for outpatients with treatment-resistant depression: Preliminary evidence for two-step intravenous dose escalation , 2017, The Australian and New Zealand journal of psychiatry.

[18]  Husseini Manji,et al.  Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study , 2016, Biological Psychiatry.

[19]  M. Frye,et al.  Concomitant Benzodiazepine Use Attenuates Ketamine Response: Implications for Large Scale Study Design and Clinical Development , 2015, Journal of clinical psychopharmacology.

[20]  K. Laws,et al.  The use of ketamine as an antidepressant: a systematic review and meta‐analysis , 2015, Human psychopharmacology.

[21]  D. Charney,et al.  Ketamine safety and tolerability in clinical trials for treatment-resistant depression. , 2015, The Journal of clinical psychiatry.

[22]  D. Luckenbaugh,et al.  Do the dissociative side effects of ketamine mediate its antidepressant effects? , 2014, Journal of affective disorders.

[23]  R. Lewis‐Fernández,et al.  Dissociative disorders in DSM‐5 , 2011, Annual review of clinical psychology.

[24]  Sidney Kennedy,et al.  Assessing full remission. , 2002, Journal of psychiatry & neuroscience : JPN.

[25]  A. Rush,et al.  When at first you don't succeed: sequential strategies for antidepressant nonresponders. , 1997, The Journal of clinical psychiatry.

[26]  C. Loo,et al.  Side-effects associated with ketamine use in depression: a systematic review. , 2018, The lancet. Psychiatry.

[27]  S. Southwick,et al.  Measurement of Dissociative States with the Clinician-Administered Dissociative States Scale (CADSS) , 1998, Journal of traumatic stress.